Drugs / BLI-489
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00909688 | Jun → Jul 2009 | — | Wyeth is now a wholly owned subsidiary of Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT00894439 | May → Jul 2009 | — | Wyeth is now a wholly owned subsidiary of Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT00854009 | Feb → Apr 2009 | — | Wyeth is now a wholly owned subsidiary of Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT00820404 | Jan → Apr 2009 | — | Wyeth is now a wholly owned subsidiary of Pfizer | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BLI-489 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00894439 ↗ |
| Modality | Small molecule | — CHEMBL4302412 ↗ |
| Route | Intravenous | “BLI-489 administered intravenously” NCT00820404 ↗ |